Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522183 · ClinicalTrials.gov registry record
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
A clinical trial of Atypical Hemolytic-Uremic Syndrome, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT01522183: Recruiting study of Atypical Hemolytic-Uremic Syndrome, sponsored by Alexion Pharmaceuticals.
NCT01522183 is a study of Atypical Hemolytic-Uremic Syndrome that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 3,000 participants, above the 53-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (5560% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522183, a study of Atypical Hemolytic-Uremic Syndrome, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Primary Outcome
To collect and evaluate safety and effectiveness data specific to the use of eculizumab or ravulizumab in aHUS patients.
Conditions Studied
Study Locations (20)
Queensland
- Clinical Trial Site - Cairns
- Clinical Trial Site - Herston
- Clinical Trial Site - Woolloongabba
Victoria
- Clinical Trial Site - Heidelberg
- Clinical Trial Site - Parkville
- Clinical Trial Site - Parkville
New South Wales
- Clinical Trial Site 1 - Westmead
- Clinical Trial Site 2 - Westmead
Western Australia
- Clinical Trial Site - Murdoch
- Clinical Trial Site - Nedlands
Colorado
- Clinical Trial Site - Aurora
District of Columbia
- Clinical Trial Site - Washington D.C.
Florida
- Clinical Trial Site - Gainesville
Georgia
- Clinical Trial Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2031-01-01 |
What NCT01522183 shows while recruiting
NCT01522183 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 53-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (5560% higher).
The record links to 1 condition, with Atypical Hemolytic-Uremic Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01522183 names 20 study sites across 14 states, led by Queensland, Victoria, New South Wales.
Frequently Asked Questions
What is clinical trial NCT01522183 about?
NCT01522183 is a clinical study titled "Atypical Hemolytic-Uremic Syndrome (aHUS) Registry". Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
What is the current status of trial NCT01522183?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2013-03-18. Estimated completion is 2031-01-01.
What conditions does trial NCT01522183 study?
This clinical trial studies the following conditions: Atypical Hemolytic-Uremic Syndrome.
Who is sponsoring clinical trial NCT01522183?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01522183 being conducted?
This trial has 20 study locations across Colorado, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Hemolytic-Uremic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI